All In Biotech

Drug Trial Radar · NCT00425360

Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC]

Last checked: Nov 19, 2026Latest source record: Aug 26, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,110 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,110

Planned (sponsor's estimate)

Start

Sep 2006

Primary completion

Not stated

Study completion Mar 2013

Sponsor

Lead sponsor
Royal Liverpool University HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Jan 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving more than one drug (combination chemotherapy) together with vaccine therapy may kill more tumor cells. It is not yet known whether chemotherapy is more effective with or without vaccine therapy in treating pancreatic cancer. PURPOSE: This randomized phase III trial is studying gemcitabine, capecitabine, and vaccine therapy to see how well they work compared with gemcitabine and capecitabine alone in treating patients with locally advanced or metastatic pancreatic cancer.

Conditions

  • Pancreatic Cancer

Interventions

  • sargramostimBiological

  • telomerase peptide vaccine GV1001Biological

  • capecitabineDrug

  • gemcitabine hydrochlorideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival at 1 year

Locations

45 sites in 1 country. Site status is shown where the registry gives one.

  • North Devon District Hospital

    Barnstaple, England, United Kingdom

  • Basingstoke and North Hampshire NHS Foundation Trust

    Basingstoke, England, United Kingdom

  • Pilgrim Hospital

    Boston, England, United Kingdom

  • Royal Bournemouth Hospital

    Bournemouth, England, United Kingdom

  • Sussex Cancer Centre at Royal Sussex County Hospital

    Brighton, England, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, England, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom

  • Darent Valley Hospital

    Dartford Kent, England, United Kingdom

  • Dorset County Hospital

    Dorchester, England, United Kingdom

  • Royal Devon and Exeter Hospital

    Exeter, England, United Kingdom

  • St. Luke's Cancer Centre at Royal Surrey County Hospital

    Guildford, England, United Kingdom

  • Huddersfield Royal Infirmary

    Huddersfield, West Yorks, England, United Kingdom

  • Ipswich Hospital

    Ipswich, England, United Kingdom

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom

  • Leicester Royal Infirmary

    Leicester, England, United Kingdom

  • Royal Liverpool University Hospital

    Liverpool, England, United Kingdom

  • Saint Bartholomew's Hospital

    London, England, United Kingdom

  • Cancer Research UK Clinical Groups at Guy's King's & St. Thomas' Hospitals

    London, England, United Kingdom

  • St. George's Hospital

    London, England, United Kingdom

  • Royal Marsden - London

    London, England, United Kingdom

  • Christie Hospital

    Manchester, England, United Kingdom

  • Clatterbridge Centre for Oncology

    Merseyside, England, United Kingdom

  • James Cook University Hospital

    Middlesbrough, England, United Kingdom

  • Northern Centre for Cancer Treatment at Newcastle General Hospital

    Newcastle upon Tyne, England, United Kingdom

  • James Paget Hospital

    Norfolk, England, United Kingdom

  • Mount Vernon Cancer Centre at Mount Vernon Hospital

    Northwood, England, United Kingdom

  • Norfolk and Norwich University Hospital

    Norwich, England, United Kingdom

  • Nottingham City Hospital

    Nottingham, England, United Kingdom

  • Churchill Hospital

    Oxford, England, United Kingdom

  • Peterborough Hospitals Trust

    Peterborough, England, United Kingdom

  • Dorset Cancer Centre

    Poole Dorset, England, United Kingdom

  • Portsmouth Oncology Centre at Saint Mary's Hospital

    Portsmouth Hants, England, United Kingdom

  • Conquest Hospital

    Saint Leonards-on-Sea, England, United Kingdom

  • Salisbury District Hospital

    Salisbury, England, United Kingdom

  • Cancer Research Centre at Weston Park Hospital

    Sheffield, England, United Kingdom

  • Wexham Park Hospital

    Slough, Berkshire, England, United Kingdom

  • Royal Marsden - Surrey

    Sutton, England, United Kingdom

  • Torbay Hospital

    Torquay Devon, England, United Kingdom

  • Royal Cornwall Hospital

    Truro, Cornwall, England, United Kingdom

  • Worthing Hospital

    Worthing, England, United Kingdom

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.